Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF -11.57%86 Intrinsic Value: Projected FCF is $10.71 as of Jul. 16, 2026, which is 59% above its 10-year median of 6.74. GuruFocus rates XVIPF with a GF Scoreâ„¢ of 86/100 and a GF Valueâ„¢ of $50.27 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 403 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 74.69% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-07-16), Xvivo Perfusion AB's Intrinsic Value: Projected FCF is $10.71. The stock price of Xvivo Perfusion AB is $26.07. Therefore, Xvivo Perfusion AB's Price-to-Intrinsic-Value-Projected-FCF of today is 2.4.
The historical rank and industry rank for Xvivo Perfusion AB's Intrinsic Value: Projected FCF or its related term are showing as below:
XVIPF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2.35 Med: 6.74 Max: 12.1
Current: 2.43
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Xvivo Perfusion AB was 12.10. The lowest was 2.35. And the median was 6.74.
XVIPF's Price-to-Projected-FCF is ranked worse than 74.69% of 403
companies
in the Medical Devices & Instruments industry
Industry Median: 1.45
vs XVIPF: 2.43
Xvivo Perfusion AB (OTCPK:XVIPF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Xvivo Perfusion AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
26.07
/
8.7235914733745
=
2.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Intrinsic Value: Projected FCF Related Terms
Xvivo Perfusion AB Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Intrinsic Value: Projected FCF Chart
XVIPF vs ABT, SYK, MDT: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Price-to-Projected-FCF falls into.
Xvivo Perfusion AB Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $10.71 mean?
Xvivo Perfusion AB (XVIPF) has a Intrinsic Value: Projected FCF of $10.71 as of Jul. 16, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Xvivo Perfusion AB and its competitors. This is 59% above median its historical median of 6.74. Over the past decade, Xvivo Perfusion AB's Intrinsic Value: Projected FCF has ranged from 2.35 to 12.10. According to the industry distribution chart, Xvivo Perfusion AB ranks #301 out of 403 companies in the Medical Devices & Instruments industry, placing it in the top 74.7%.
Is Xvivo Perfusion AB's Intrinsic Value: Projected FCF too high?
Xvivo Perfusion AB's current Intrinsic Value: Projected FCF of $10.71 is 59% above median its 10-year median of 6.74. Over the past 10 years, this metric has ranged from a low of 2.35 to a high of 12.10. The Medical Devices & Instruments industry median Intrinsic Value: Projected FCF is 1.45. Xvivo Perfusion AB's value of $10.71 is 638.6% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #301 out of 403 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xvivo Perfusion AB has a GF Scoreâ„¢ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Intrinsic Value: Projected FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #301 out of 403 companies for Intrinsic Value: Projected FCF. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.45. Xvivo Perfusion AB's value of $10.71 is 638.6% above this benchmark. Historically, Xvivo Perfusion AB's own Intrinsic Value: Projected FCF has ranged from 2.35 to 12.10 over the past decade. While the company's 10-year median is 6.74 vs. the industry median of 1.45, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.45, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Intrinsic Value: Projected FCF of $10.71 is 638.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Intrinsic Value: Projected FCF is $10.71, which is 59% above median its own 10-year median of 6.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.27, compared to a current price of $26.07 — trading 48.1% below its estimated fair value. The current Intrinsic Value: Projected FCF is $10.71, which is 59% above median its 10-year median of 6.74 and 638.6% above the Medical Devices & Instruments industry median of 1.45. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Intrinsic Value: Projected FCF is $10.71 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $26.07 is trading 48.1% below its estimated GF Value™ of $50.27.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Intrinsic Value: Projected FCF: $10.71 (59% above median its 10-year median of 6.74)
GF Value™: $50.27 vs. price of $26.07 (48.1% below fair value)
Industry Position: 638.6% above the Medical Devices & Instruments median (#301 of 403)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
